Skip to content

Relationship between Demodex and blepharitis

Demodex Folliculorum Infestation in Meibomian Gland Dysfunction Related Dry Eye Patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056628
Enrollment
Unknown
Registered
2022-02-09
Start date
2020-06-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blepharitis

Interventions

experimental group:none
control group:none

Sponsors

Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in this clinical study and sign the informed consent form; 2. No gender limit, age 18-70 years; 3. Patients clinically diagnosed as blepharitis have not received local or systemic anti-mite treatment in the past 14 days; 4. Other options of the study eye: the right eye of the patient; 5. Have not participated in other drug clinical trials within 2 weeks of the trial; 6. He is not using other drugs to treat dry eyes, or is using other drugs to treat dry eyes but has stopped taking drugs for more than 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Clinically, it is supposed to be a patient with fungal, bacterial or viral keratoconjunctivitis in active stage; 2. Those with other obvious conjunctival, corneal and iris lesions; 3. Tear film rupture time=0 seconds, or tear secretion test=0 mm/5 minutes; 4. The number of staining points of the whole cornea is more than 30, and there is flaky color fusion or filamentous matter; 5. Complicated with severe primary diseases such as heart, cerebrovascular, liver, kidney and hematopoietic system; 6. Those who have internal eye surgery or eye injury in the past six months; 7. The patient received embolization of lacrimal dots in the last month; 8. Patients with a history of HSK infection; 9. Treatment that may affect the results (such as systemic steroid hormone and immunosuppressive treatment); 10. Long-term systemic or ocular administration may affect the study and evaluation of patients; 11. Sjogren's syndrome, systemic diseases and other eye diseases affecting the efficacy evaluation; 12. The researcher believes that there are any reasons for not participating in the test.

Design outcomes

Primary

MeasureTime frame
symptoms grading;lid margin signs;conjunctival signs;corneal signs;

Countries

China

Contacts

Public ContactLei Tian

Beijing Tongren Hospital, Capital Medical University

tianlei0131@163.com+86 18600166885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026